Core Insights - Adia Nutrition Inc. is hosting a virtual presentation in collaboration with the Center for Autism and Related Disabilities (CARD) at UCF to discuss its clinical study on Autism Spectrum Disorder (ASD) [1][2][3] Group 1: Clinical Study and Presentation - The clinical study, identified as ClinicalTrials.gov ID: NCT07304440, is a 24-month trial recruiting children aged 3-12 with ASD, evaluating the efficacy of AdiaVita, which includes umbilical cord blood-derived stem cells and exosomes combined with glutathione [2][4] - The presentation aims to provide families, caregivers, and professionals with critical information about the study, emphasizing the safety and domestic nature of the trial [3][4] - Dr. Terri Daly from UCF CARD highlighted the strong community interest in the event, which offers parents a chance to learn about a U.S.-based study for potential enrollment [3][4] Group 2: Company Overview and Mission - Adia Nutrition Inc. specializes in regenerative medicine and offers products like AdiaVita and AdiaLink through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products [7][8] - The company operates Adia Med clinics that focus on orthopedic, pain management, and wound repair, providing advanced regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP) [7][8] - Revenue is generated through service fees, product sales, equity stakes, and insurance billing for healthcare treatments, with a commitment to standardized, FDA-approved lab protocols [8]

Core Insights - Adia Nutrition Inc. has appointed Amy Dalrymple as the leader of its new Regenerative Aesthetics Division, reflecting the company's strategic expansion into the aesthetics market [1][4][6] Group 1: Leadership Appointment - Amy Dalrymple, MSN, APRN, FNP-C, brings over a decade of specialized experience in aesthetic medicine and plastic surgery, including advanced non-surgical rejuvenation techniques [2][3] - Dalrymple will oversee and perform all procedures in the new division, focusing on advanced facial rejuvenation and hair restoration [2][6] Group 2: Market Expansion - The appointment of Dalrymple aligns with Adia Med's growth into cosmetics and regenerative aesthetics, addressing the rising demand for minimally invasive solutions [4][6] - The first patient treatments in the Regenerative Aesthetics Division are set to begin on April 6, 2026, with limited spaces for consultations and procedures [6] Group 3: Company Overview - Adia Nutrition Inc. specializes in stem cell and regenerative products, with a focus on expanding its clinic network and offering advanced treatments like stem cell therapies and platelet-rich plasma (PRP) [10][11] - The company generates revenue through service fees, product sales, and insurance billing for healthcare treatments, while also investing in aligned businesses [11]

Core Insights - Adia Nutrition's subsidiary, Adia Med, has launched a digital refresh of its online presence through a partnership with ZenChange Marketing, focusing on transparency and accessibility in its investigational studies [1][3] - The redesigned website serves as a hub for Adia Med's clinical research efforts, featuring intuitive navigation and educational content on stem cell therapies [3] - A key feature of the site is the Autism Stem Cell Clinical Study, which is currently recruiting participants and involves a 24-month study examining the effects of AdiaVita stem cells in children with Autism Spectrum Disorder [4][5] Company Overview - Adia Med is advancing regenerative medicine through innovative therapies and structured clinical research, emphasizing transparency, medical oversight, and participant safety [8] - The organization has adopted a patient-pay model for its studies, allowing for greater control over research timelines and potential future insurance coverage for regenerative therapies [5] - Adia Nutrition Inc. specializes in stem cell and regenerative products, with a focus on expanding its clinics and services across the nation [11][12] Marketing and Outreach - ZenChange Marketing has taken over the management of Adia Med's social media channels to ensure consistent and engaging content delivery [3] - The updated website includes detailed study summaries, eligibility criteria, and enrollment information, aimed at educating families and healthcare professionals [3][4] - Adia Med encourages strategic partnerships with clinic owners and healthcare practitioners to expand access to its regenerative therapies [10]

Core Viewpoint - Adia Nutrition Inc. has submitted a final revised protocol for a clinical study on lower back pain to the Institutional Review Board (IRB), following positive feedback on the initial submission, and is optimistic about receiving approval soon [1][3][6]. Group 1: Clinical Study Details - The clinical study focuses on evaluating AdiaVita's potential to reduce inflammation and support tissue repair in the lower back, utilizing a single-blind, placebo-controlled design with approximately 100 participants [7]. - The patient-pay model for participation is set at $5,000 per participant, with no additional costs for the crossover phase [4]. - The study will involve a crossover design where participants initially receiving a placebo will later receive AdiaVita after the initial treatment period [7]. Group 2: Ongoing Research and Development - Adia Med is also conducting an IRB-approved 24-month study on Autism Spectrum Disorder (ASD), actively recruiting children aged 3-12, which examines the combination of AdiaVita with glutathione therapy [5]. - The company is focused on expanding access to advanced regenerative therapies and is open to strategic partnerships for licensing and integrating its therapies into other practices [8]. Group 3: Company Overview - Adia Nutrition Inc. specializes in regenerative medicine and therapeutic solutions, including stem cell and regenerative products like AdiaVita and AdiaLink, and operates clinics focused on orthopedic and pain management [9][10]. - Revenue streams include service fees, product sales, equity stakes, and insurance billing for healthcare treatments, with a commitment to standardized, FDA-approved lab protocols [10].

Core Insights - Adia Nutrition Inc. is expanding its clinical research pipeline with plans to launch four to five new studies in 2026, focusing on regenerative therapies using Adia Vita, which is derived from umbilical cord blood [1][4]. Clinical Research Expansion - The planned studies will be conducted at the Adia Med clinic in Winter Park, Florida, and in collaboration with partner clinics across the U.S. [3] - The company is actively seeking Institutional Review Board (IRB) approvals to facilitate multi-site participation for these studies [3][4]. Focus Areas of New Studies - Priority efforts include expanding the existing Autism Spectrum Disorder (ASD) study to include children aged 13, and launching a new study on the effects of Adia Vita in patients with rheumatoid arthritis [8]. - The ongoing ASD study is actively recruiting children aged 3-12 and has received IRB approval [4]. Business Model and Revenue Generation - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments [9]. - The company is also investing in aligned businesses, such as Cement Factory LLC, to enhance its focus on health and wellness [9]. Commitment to Ethical Standards - All research conducted by Adia Med is under strict ethical oversight, informed consent, and regulatory compliance [5]. - The company emphasizes its commitment to advancing regenerative medicine through rigorous and ethical clinical research [4]. Strategic Partnerships - Adia Med is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing its name or integrating its regenerative therapies into their practices [6]. - Collaborations with leading clinics are aimed at accelerating IRB approvals and broadening patient access [4].

Core Viewpoint - Adia Nutrition Inc. has achieved a significant milestone by having its Form 10 registration statement become effective, transitioning the company to full reporting status under SEC regulations, which enhances transparency and prepares for potential uplisting to NASDAQ [1][2][3] Group 1: Company Developments - The Form 10 was filed on December 5, 2025, and became effective automatically 60 days later without further SEC review, marking a transition to full reporting status [2] - CEO Larry Powalisz emphasized that this achievement reflects the company's commitment to governance and investor confidence, while also accelerating preparations for uplisting to NASDAQ [3] - The company is expanding its regenerative medicine platform and clinic network, focusing on advanced treatments in stem cell therapy [3] Group 2: Financial and Operational Highlights - Adia Nutrition generates revenue through service fees, product sales, equity stakes, and insurance billing for healthcare treatments [7] - The company is experiencing significant revenue growth and operational expansion in 2025, positioning itself for continued momentum in personalized healthcare [8] - Adia Nutrition is also investing in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness [7] Group 3: Strategic Partnerships and Initiatives - The company is encouraging clinic owners and healthcare practitioners to license the Adia Med name or integrate its regenerative therapies into their practices [5] - Adia Nutrition is forming strategic partnerships to expand access to advanced stem cell solutions [5] - The company is involved in ongoing clinical studies, including an IRB-approved study on autism spectrum disorder using regenerative stem cell therapy [8]

Core Insights - Adia Nutrition Inc. has appointed Dr. Brian L. Browning as the lead physician for orthopedic treatments at Adia Med, enhancing its leadership in regenerative medicine and orthopedic specialties [1][6][8] Group 1: Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded, focusing on advancing healthcare through innovative regenerative medicine solutions [8] - The company specializes in stem cell and regenerative products, including AdiaVita and AdiaLink, and is expanding its offerings to include insurance-billable wound care products [8][9] - Adia Med clinics provide specialized treatments in orthopedic care, pain management, and wound repair, integrating advanced regenerative therapies [8][9] Group 2: Leadership and Expertise - Dr. Browning has extensive experience in orthopedic regenerative treatments and a strong background in family medicine and neuromusculoskeletal medicine [4][5] - He has been involved in training physicians and has a patient-centered approach, which positions Adia Med to offer comprehensive non-surgical regenerative solutions [6][8] Group 3: Services and Treatments - Under Dr. Browning's leadership, Adia Med will offer advanced regenerative treatments such as stem cell therapy, platelet-rich plasma (PRP) therapy, and ultrasound-guided injections for various orthopedic conditions [5][6] - The clinic's services are designed to integrate seamlessly with Adia Med's flagship stem cell therapies, focusing on pain management, sports injuries, and tissue regeneration [5][6] Group 4: Strategic Partnerships and Growth - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies [7] - The company aims to expand access to advanced stem cell solutions as part of its mission to revolutionize healthcare and promote holistic wellness [9]

Core Insights - Adia Nutrition Inc. is set to release a documentary featuring professional wrestler Jeff Sciullo's recovery from a tricep injury, highlighting the effectiveness of its regenerative therapy product, AdiaVita [1][3][5] Company Overview - Adia Nutrition Inc. is based in Winter Park, Florida, and is publicly traded under the ticker OTCQB: ADIA, focusing on advancing healthcare through innovative stem cell and regenerative products [8] - The company operates through its lab division, Adia Labs LLC, and is expanding its services to include insurance-billable wound care products [8] - Adia Med clinics specialize in orthopedic, pain management, and wound repair, offering advanced regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP) [8] Product Details - AdiaVita is a high-potency stem cell product that delivers over 100 million umbilical cord-derived stem cells and more than 3 trillion exosomes per dose, aimed at promoting rapid tissue repair and reducing recovery time for athletes [1][5] - The documentary will showcase the real-world results of the AdiaVita treatment, emphasizing its role in accelerating healing and improving recovery outcomes in sports medicine [5][6] Strategic Partnerships - The documentary is produced in collaboration with The Dr. Asa Network, which is known for its focus on health media and regenerative medicine, enhancing the visibility of Adia's treatments [3][5] - Adia Nutrition Inc. is open to strategic partnerships with clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating its regenerative therapies into their practices [7] Revenue Generation - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, indicating a diversified income stream [9] - Adia Nutrition Inc. also invests in aligned businesses, such as Cement Factory LLC, which focuses on health and wellness, further expanding its market presence [9]

Core Insights - Adia Nutrition Inc. is conducting an IRB-approved clinical study for children with Autism Spectrum Disorder (ASD) using umbilical cord blood-derived stem cell and exosome treatments, known as AdiaVita, combined with glutathione to evaluate improvements in ASD symptoms [1][2][3] Study Details - The study is a 24-month randomized, crossover trial targeting approximately 100 children aged 3-12 with confirmed ASD, with primary outcomes focused on changes in Autism Treatment Evaluation Checklist (ATEC) scores [2] - Participants in the active arm will receive three monthly infusions of AdiaVita plus glutathione, while the comparator arm will start with glutathione alone, with crossover options later [2] Previous Results - The trial builds on promising results from a 2025 study involving five children, where families reported significant symptom improvements, including one child with an ATEC score reduction of over 40 points [3] Participation and Costs - Enrollment requires a one-time fee of $12,000, covering all treatments and procedures for both phases of the study, with no monetary incentives offered [4] - The study is designed to ensure that all children receive the full treatment regardless of their initial group, provided they meet safety criteria [4] Global Participation - The trial welcomes children from across the United States and worldwide, reflecting the company's commitment to broad access to regenerative research [5] Company Commitment - The CEO of Adia Nutrition emphasized the company's dedication to transparent and ethical research aimed at supporting children with autism and their families [6] Company Overview - Adia Nutrition Inc. specializes in stem cell and regenerative products, operating through its lab division, Adia Labs LLC, and expanding its services to include insurance-billable wound care products [8] - The company generates revenue through service fees, product sales, and billing insurance for healthcare treatments, while also investing in aligned businesses [9]

Core Viewpoint - Adia Nutrition Inc. has received notification from the SEC that its Form 10 registration statement will automatically become effective on February 3, 2026, marking a significant milestone in its transition to full SEC reporting status [1][2][4]. Group 1: SEC Registration and Reporting - The Form 10 was originally filed on December 5, 2025, and its effectiveness will enhance transparency for investors through regular audited financial disclosures, including annual reports on Form 10-K and quarterly reports on Form 10-Q [2][4]. - The notification from the SEC is seen as a major step forward for Adia Nutrition, as it will provide investors with increased confidence and transparency starting February 3 [3][4]. Group 2: Business Operations and Growth Strategy - Adia Nutrition focuses on delivering innovative healthcare solutions through its divisions, including Adia Med clinics that specialize in advanced stem cell therapies and Adia Labs that provide biologic products to healthcare providers [5][7]. - The company generates revenue through service fees, product sales, equity stakes, and billing insurance for healthcare treatments, while also investing in aligned businesses like Cement Factory LLC [8]. Group 3: Future Prospects and Strategic Partnerships - The effectiveness of the Form 10 will trigger standard SEC reporting obligations, aligning Adia with best practices in public company disclosure and positioning it to meet eligibility requirements for potential listing on a national exchange [4]. - The company encourages clinic owners and healthcare practitioners to explore licensing the Adia Med name or integrating its regenerative therapies into their practices, indicating a focus on strategic partnerships to expand access to advanced stem cell solutions [6].